{
    "organizations": [],
    "uuid": "25e15e08f5999a4c9a99618188ba2bdba5cc742c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-theravance-mylan-announce-fda-acce/brief-theravance-mylan-announce-fda-acceptance-of-marketing-application-for-revefenacin-idUSASB0C2R6",
    "ord_in_thread": 0,
    "title": "BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Theravance Biopharma Inc:\n* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T21:32:00.000+02:00",
    "crawled": "2018-01-30T18:59:13.021+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "theravance",
        "biopharma",
        "inc",
        "theravance",
        "biopharma",
        "mylan",
        "announce",
        "fda",
        "acceptance",
        "new",
        "drug",
        "application",
        "revefenacin",
        "adult",
        "chronic",
        "obstructive",
        "pulmonary",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}